Helping patients live longer, better.
ERYTECH is a clinical-stage biopharmaceutical company that developed innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Founded in Lyon, France in 2004, the company focused on encapsulating therapeutic agents inside red blood cells to reduce toxicity and improve efficacy. ERYTECH was listed on the Nasdaq Capital Market and Euronext Paris. The company later merged with PHERECYDES to form PHAXIAM Therapeutics, which subsequently entered judicial restructuring in 2025.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2020
Nov 2017
Apr 2017
Dec 2015
Oct 2014
Apr 2013
Create a free account to see which investors have funded this company.
Create Free Account
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...
Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe...
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally ava...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
